Liechtenstein

11 Vaccines Approved for Use in Liechtenstein

• Novavax
  Nuvaxovid

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 40 countries

  22 trials in 14 countries

  Approval Source: ema.europa.eu

  Protein Subunit

• Sanofi/GSK
  VidPrevtyn Beta

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 30 countries

  3 trials in 2 countries

  Approval Source: ema.europa.eu

  Protein Subunit

• Moderna
  Spikevax

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 88 countries

  70 trials in 24 countries

  Approval Source: ema.europa.eu

  RNA

• Moderna
  Spikevax Bivalent Original/Omicron BA.1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 38 countries

  5 trials in 4 countries

  Approval Source: ema.europa.eu

  RNA

• Moderna
  Spikevax Bivalent Original/Omicron BA.4/BA.5

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 33 countries

  2 trials in 1 country

  Approval Source: ema.europa.eu

  RNA

• Pfizer/BioNTech
  Comirnaty

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 149 countries

  100 trials in 31 countries

  Approval Source: ema.europa.eu

  RNA

• Pfizer/BioNTech
  Comirnaty Bivalent Original/Omicron BA.1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 35 countries

  3 trials in 5 countries

  Approval Source: ema.europa.eu

  RNA

• Pfizer/BioNTech
  Comirnaty Bivalent Original/Omicron BA.4/BA.5

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 33 countries

  4 trials in 1 country

  Approval Source: ema.europa.eu

  RNA

• Janssen (Johnson & Johnson)
  Jcovden

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 113 countries

  26 trials in 25 countries

  Approval Source: ema.europa.eu

  Non Replicating Viral Vector

• Oxford/AstraZeneca
  Vaxzevria

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 149 countries

  73 trials in 34 countries

  Approval Source: ema.europa.eu

  Non Replicating Viral Vector

• Valneva
  VLA2001

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 33 countries

  9 trials in 4 countries

  Approval Source: ema.europa.eu

  Inactivated

0 Vaccines in Clinical Trials in Liechtenstein